66PPharmacological activity of CB-103: An oral pan-NOTCH inhibitor targeting the NOTCH transcription complex. (5th March 2018) - Weber, D; Lehal, R; Frismantas, V; Bourquin, J-P; Bauer, M; Murone, M; Radtke, F